Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
Список исп. литературыСкрыть список 1. Колюцкая Е.В., Стась С.Ю. Эсциталопрам в терапии панического расстройства. Психиатр. и психофармакотер. 2006; 1: 20–2. / Koliutskaia E.V., Stas' S.Iu. Estsitalopram v terapii panicheskogo rasstroistva. Psikhiatr. i psikhofarmakoter. 2006; 1: 20–2. 2. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry 1998; 155: 1–34. 3. Asnis GM, Hameedi FA, Goddard AW et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001; 103: 1–14. 4. Ballenger JC, Wheadon DE, Steiner M et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42. 5. Bandelow B, Zohar J, Hollander E et al. Task forse on treatment guidelines for anxiety. World J Biolog Psychiatry 2008; 9 (4): 248–312. 6. Burke WJ, Gergel I, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6. 7. Davidson J, Bose A, Su G. Escitalopram in the treatment of generalized anxiety disorder. Abstr. Int J Neuropsychopharmacol 2002; 5: 214. 8. Goddard AW, Charney DS. SSRIs in the treatment of panic disorder. Depress Anxiety 1998; 8 (Suppl. 1): 114–20. 9. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7: 40–4. 10. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: Role of human cyto-chromes P450. J Clin Psychiatry 1998; 59 (Suppl. 15): 19–27. 11. Hyttel J, Bogeso KP, Perregaard J et al. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88: 157–60. 12. Kasper S, Loft H, Smith JR. Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. Int J Neuropsychopharmacol 2002; 5: 131. 13. Kasper S, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001; 11: 307–21. 14. Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 145–52. 15. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 153–60. 16. Leinonen E, Lepola U, Koponen H et al. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000; 25: 25–32. 17. Lepola UM, Wade AG, Leinonen EV et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59: 528–34. 18. Lesser IM, Rubin RT, Pecknold JC et al. Secondary depression in panic disorder and agoraphobia. Pt. 1: Frequency, severity, and response to treatment. Arch Gen Psychiatry 1988; 45: 437–43. 19. Londborg PD, Wolkow R, Smith WT et al. Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54–60. 20. Lydiard RB. Effects of escitalopram on anxiety symptoms in depression. World J Biol Psychiatry 2001; 2: 1. 21. Michelson D, Allgulander C, Dantendorfer K et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Stahl et al. randomised, placebo-controlled trial. Br J Psychiatry 2001; 179: 514–8. 22. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–61. 23. Mountjoy CQ, Roth M, Garside RF et al. A clinical trial of phenelzine in anxiety depressive and phobic neuroses. Br J Psychiatry 1977; 131: 486–92. 24. Owens M, Rosenbaum J. Escitalopram: A second-generation SSRI. CNS Spectrums 2002; 7: 34–39. 25. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345–50. 26. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998; 155: 1189–95. 27. Pollack MH, Marzol PC. Panic: course, complications and treatment of panic disorder. J Psychopharmacol 2000; 14: 25–30. 28. Pollack MH, Otto MW, Worthington JJ et al. Sertraline in the treatment of panic disorder: A flexible-dose multicenter trial. Arch Gen Psychiatry 1998; 55: 1010–6. 29. Roy-Byrne P, Wingerson D, Cowley D et al. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am 1993; 16: 719–35. 30. Rosenthal MH, Li D. Efficacy and tolerability of escitalopram in patients intolerant of other SSRIs. Poster presented at: 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum. Montreal, Canada 2002. 31. Stahl SM, van Gergel I, Dayong L. Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322–7. 32. Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry 2002; 63: 854–5. 33. Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 2002; 63: 656–7. 34. Starcevic V. Anxiety states: A review of conceptual and treatment issues. Curr Opin Psychiatry 2006; 19 (1): 79–83. 35. Tyrer P, Candy J, Kelly D. Phenelzine in phobic anxiety: A controlled trial. Psychol Med 1973; 3: 120–4. 36. Wade AG, Lepola U, Koponen HJ et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–53. 37. Wade A, Lemming OM, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102. 38. Zohar J, Westenberg HG. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 39–49.